Cash Flow Statement (Annual)

LOGL / Legend Oil and Gas, Ltd Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2010 2011 2012 2013 2014 2015 2016
Cash Flows From Operating Activities
  Net Income Loss -158 -6,049 -9,281 -12,331 -2,356 -14,990 -7,085
  Adjustments To Reconcile Net Loss To Cash Flows From Operating Activities
    Share Based Compensation - 1,465 1,386 1,468 811 0 11
    Asset Retirement Obligation Accretion Expense - 15 59 63 16 28 44
    Share Based Goods And Nonemployee Services Transaction Cash Flow Effects - 20 152 - - - -
    Business Combination Acquisition Related Costs - 1,404 4,147 0 - - -
    Depletion Depreciation Amortization And Impairment - 2,052 2,115 8,207 - - -
  Changes In Operating Assets And Liabilities
    Increase Decrease In Accounts Receivable 11 377 -94 27 -257 -952 51
    Increase Decrease In Prepaid Deferred Expense And Other Assets 23 71 15 -3 -48 243 -
    Increase Decrease In Accounts Payable 12 485 1,067 275 -90 218 -292
  Net Cash Provided By Used In Operating Activities -175 -1,057 -532 -1,416 -1,823 -2,536 -3,221
Cash Flows From Investing Activities
  Payments To Explore And Develop Oil And Gas Properties - 253 508 930 1,200 856 -
  Net Cash Provided By Used In Investing Activities -629 -9,043 1,608 1,130 -984 -758 -570
Cash Flows From Financing Activities
  Proceeds From Repayments Of Notes Payable - 5,094 -1,392 -1,310 - - -
  Net Cash Provided By Used In Financing Activities 904 10,094 -970 -108 3,445 3,056 3,488
  Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Change - -6 106 -394 - - -
  Effect Of Exchange Rate On Cash And Cash Equivalents - -42 -146 446 - - -
  Cash And Cash Equivalents Period Increase Decrease 100 -48 -40 51 638 -238 -302
Cash And Cash Equivalents At Carrying Value - 53 13 64 702 464 161
Supplemental Disclosures Of Cash Flow Information
  Cash Paid During The Year For
  Interest Paid 2 37 220 124 21 5 34

Peers - Drilling Oil and Gas Wells (1381)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 52490C101